Intersect ENT Inc (NASDAQ:XENT) COO Richard E. Kaufman sold 50,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $33.33, for a total transaction of $1,666,500.00. Following the transaction, the chief operating officer now owns 107,470 shares in the company, valued at approximately $3,581,975.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of Intersect ENT Inc (NASDAQ XENT) opened at $34.55 on Friday. The firm has a market cap of $1,001.50, a PE ratio of -54.84 and a beta of 0.67. Intersect ENT Inc has a 52 week low of $11.75 and a 52 week high of $35.34.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. The business had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The firm’s revenue for the quarter was up 20.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. equities analysts anticipate that Intersect ENT Inc will post -0.63 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on XENT shares. BidaskClub downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Canaccord Genuity restated a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th. JPMorgan Chase & Co. upgraded shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Guggenheim restated a “buy” rating and set a $41.00 price objective on shares of Intersect ENT in a report on Friday, December 15th. Finally, Zacks Investment Research downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. Intersect ENT currently has an average rating of “Buy” and a consensus target price of $33.38.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its stake in Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after acquiring an additional 1,056,389 shares during the period. Vanguard Group Inc. increased its stake in Intersect ENT by 6.7% in the second quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock valued at $31,853,000 after acquiring an additional 71,750 shares during the period. Alliancebernstein L.P. increased its stake in Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after acquiring an additional 898,785 shares during the period. Neuberger Berman Group LLC increased its stake in Intersect ENT by 8.0% in the third quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock valued at $24,999,000 after acquiring an additional 59,620 shares during the period. Finally, State Street Corp increased its stake in Intersect ENT by 33.6% in the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock valued at $15,437,000 after acquiring an additional 138,968 shares during the period. 86.31% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.truebluetribune.com/2018/01/21/insider-selling-intersect-ent-inc-xent-coo-sells-1666500-00-in-stock.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.